26 April 2016 - And why that may be bad for Pfizer, Merck, and, yes, Valeant’s investors.

Drug company investors may be worried about the industry’s wrong ailment.

On Wednesday, the soon-to-step-down CEO of controversial drug company Valeant Pharmaceuticals Michael Pearson testified in front of a Senate panel investigating Valeant and other companies that have made a practice of increasing the prices of older drugs. 

Investors last year were spooked about the growing scrutiny by Washington and regulators on drug prices. But even as the Senate is digging in, the real problem for big pharma companies, like AstraZeneca, Pfizer, and Merck, may be that their ability to enforce higher prices has actually come to an end.

For more details, go to: http://fortune.com/2016/04/26/drug-prices-valeant-pfizer-merck/